Search research articles
Contact Us
Filters
Showing results (21-30 of 42) with videos related to
Page
of 5
Sort By:
Breast Cancer Research : BCR
|
February 9, 2013
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
Carsten Denkert, Jens Huober, Sibylle Loibl, et al.
Breast Cancer Research : BCR
|
April 15, 2014
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial
Miguel Martin, Jan C Brase, Lourdes Calvo, et al.
The Lancet. Oncology
|
February 15, 2021
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study
Mahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, et al.
BMC Cancer
|
October 9, 2012
Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test
Ralf Kronenwett, Kerstin Bohmann, Judith Prinzler, et al.
The Lancet. Oncology
|
February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Reinhard Dummer, Jan C Brase, James Garrett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 28, 2011
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy
Sarah Minner, Malaika Enodien, Hüseyin Sirma, et al.
Breast Cancer Research and Treatment
|
February 25, 2016
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
Miguel Martin, Jan C Brase, Amparo Ruiz, et al.
Nature Medicine
|
October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
Cancer Research Communications
|
March 21, 2025
The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Benjamin J Solomon, Daniel S W Tan, Gilberto de Castro, et al.
JAMA Oncology
|
September 30, 2016
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Debora Fumagalli, David Venet, Michail Ignatiadis, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 42) with videos related to
Sort By:
Page
of 5
Breast Cancer Research : BCR
|
February 9, 2013
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
Carsten Denkert, Jens Huober, Sibylle Loibl, et al.
Breast Cancer Research : BCR
|
April 15, 2014
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial
Miguel Martin, Jan C Brase, Lourdes Calvo, et al.
The Lancet. Oncology
|
February 15, 2021
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study
Mahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, et al.
BMC Cancer
|
October 9, 2012
Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test
Ralf Kronenwett, Kerstin Bohmann, Judith Prinzler, et al.
The Lancet. Oncology
|
February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Reinhard Dummer, Jan C Brase, James Garrett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 28, 2011
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy
Sarah Minner, Malaika Enodien, Hüseyin Sirma, et al.
Breast Cancer Research and Treatment
|
February 25, 2016
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
Miguel Martin, Jan C Brase, Amparo Ruiz, et al.
Nature Medicine
|
October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
Cancer Research Communications
|
March 21, 2025
The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Benjamin J Solomon, Daniel S W Tan, Gilberto de Castro, et al.
JAMA Oncology
|
September 30, 2016
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Debora Fumagalli, David Venet, Michail Ignatiadis, et al.
Page
of 5